RxDoctor Payments Data

Peter Yang, MD

Family Medicine · Alhambra, CANPI 1174183230

Payments from drug & device makers

$458in general payments, 2019–2025

Across 25 payments — averaging $18.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$108
  • Amgen$89
  • Bayer$38
  • Exact Sciences$35
  • Merck$29
  • Axsome Therapeutics, Inc.$27
  • plus $131 from 8 others

What the payments were for

  • Food & beverage$458100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$458 in reported general payments places this provider in the 60th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$19,207
Medicare patients
89
Services billed
184

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban134$106,682
RybelsusSemaglutide22$41,197
OzempicSemaglutide24$38,284
MounjaroTirzepatide25$33,797
JardianceEmpagliflozin27$31,406
TrulicityDulaglutide20$25,873
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$17,605
XareltoRivaroxaban17$15,908
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$14,915
SymbicortBudesonide/Formoterol Fumarate34$11,375
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr22$10,385
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate16$5,327
Insulin Lispro Kwikpen U-100Insulin Lispro22$4,919
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen97$3,965
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$3,839

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$106,682134 claims
Lilly USA, LLCMounjaro, Trulicity$108$59,67045 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arexvy$19$31,55856 claims
Johnson & JohnsonXarelto$21$15,90817 claims
AstraZenecaSymbicort$16$11,37534 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 10,533 family medicine providers in California.

Other family medicine in Alhambra

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →